Output Catalog
ASAP is committed to accelerating the pace of discovery and informing a path to a cure for Parkinson’s disease through collaboration, research-enabling resources, and data sharing. We’ve created this catalog to showcase the research outputs and tools developed by ASAP-funded programs.
-
Output Type
-
Program
-
CRN Team Name
-
Theme
Adult-specific Reelin expression alters striatal neuronal organization: implications for neuropsychiatric disorders
Reelin levels might modulate the numbers of striatal interneurons and the density of the nigrostriatal dopaminergic projections, suggesting that these changes may be involved in the protection of Reelin against neuropsychiatric disorders.
Rapid iPSC inclusionopathy models shed light on formation, consequence, and molecular subtype of α-synuclein inclusions
The authors developed an iPSC toolbox utilizing piggyBac-based or targeted transgenes to rapidly induce CNS cells with concomitant expression of aggregation-prone proteins.
Neuromelanin accumulation drives endogenous synucleinopathy in non-human primates
A new NHP PD model was developed by inducing neuromelanin (NM) accumulation in dopaminergic neurons, leading to synucleinopathy and neuron degeneration similar to human PD neuropathology. Lowering NM levels may offer PD therapeutic strategies.
Modelling human brain-wide pigmentation in rodents recapitulates age-related multisystem neurodegenerative deficits
Authors describe an animal model of human-like neuromelanin pigmentation. The animals display age-related neuronal dysfunction and degeneration affecting numerous brain circuits and body tissues.
In vivo reduction of age-dependent neuromelanin accumulation mitigates features of Parkinson’s disease
Humanized rodents with neuromelanin can develop Parkinson's symptoms. Reducing neuromelanin accumulation mitigates PD features, showing a link between NM levels and disease pathology.
Non-ablative disease-modifying effects of magnetic resonance-guided focused ultrasound in neuromelanin-producing parkinsonian rodents
The authors' findings indicate that tFUS treatment applied at prodromal/early disease stages provides extended structural and functional preservation of the nigrostriatal pathway in neuromelanin-producing parkinsonian rats.
Local diffusion in the extracellular space of the brain
The authors highlight emerging technological advances to respectively interrogate and model diffusion through the ECS, and point out how these may contribute in resolving the remaining enigmas of the ECS.
Dopamine neuron activity encodes the length of upcoming contralateral movement sequences
Here the authors investigate whether dopamine neurons encode a general motivation signal or modulate movement kinematics.
Neuronal dysfunction and gene modulation by non-coding RNA in Parkinson’s disease and synucleinopathies
This review discusses recent literature focused on the role of RNA-based mechanisms involved in different aspects of neuronal pathology in Parkinson’s disease and synucleinopathy models.
Systemic inflammation triggers long-lasting neuroinflammation and accelerates neurodegeneration in a rat model of Parkinson’s disease overexpressing human alpha-synuclein
In the present study, the authors assessed the development of PD-like symptoms on a PD rat model overexpressing human α-synuclein at a presymptomatic age, exposed to a pro-inflammatory insult by injection of lipopolysaccharide.
Fluorescence Microscopy Shadow Imaging for Neuroscience
This review highlights the inherent limitations of fluorescence microscopy and conventional labeling and summarizes the pros and cons of recent shadow imaging approaches.
The VEGFs/VEGFRs system in Alzheimer’s and Parkinson’s diseases: Pathophysiological roles and therapeutic implications
This article focuses on the VEGFs/VEGFRs involvement in neurodegenerative diseases by reviewing the current literature on the rather complex VEGFs/VEGFRs contribution to the pathogenic mechanisms of Alzheimer’s (AD) and Parkinson’s disease (PD).
Development and characterization of a non-human primate model of disseminated synucleinopathy
The intraputaminal delivery of AAV9-SynA53T resulted in a widespread synucleinopathy throughout the cerebral cortex and substantia nigra in the non-human primate brain.
Functional efficacy of the MAO-B inhibitor safinamide in murine substantia nigra pars compacta dopaminergic neurons in vitro: a comparative study with tranylcypromine
Safinamide (SAF) is used for PD by enhancing dopamine signal. SAF prolongs recovery from dopamine-mediated firing inhibition in SNpc DAergic neurons, mildly compared to tranylcypromine, suggesting multiple sites of action for SAF's therapeutics.
The Role of Alpha-Synuclein Pathology
Alpha-Synuclein (aSyn) is key protein in PD and other synucleinopathies, causing neurodegeneration. Despite its importance, there is a lack of consensus on markers to define aSyn aggregates, highlighting the need for better research tools and models.
